Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18390887 | 0.82 | HRH3 (0.53) | HRH3KCNH2CYP2D6 | |
| SCHEMBL27812244 | 0.78 | ALDH1A1 (0.43) | F13A1TGM2TGM1ALDH1A1DPP4 | |
| SCHEMBL18390871 | 0.74 | CYP1A2 (0.46) | F13A1TGM2TGM1ALDH1A1MAPT | |
| SCHEMBL19493242 | 0.74 | PIK3CD (0.47) | HRH3KCNH2CYP2D6ALDH1A1 | |
| SCHEMBL25815899 | 0.73 | DPP4 (0.38) | CYP2D6ALDH1A1DPP4DPP7 | |
| SCHEMBL22680739 | 0.72 | HRH3 (0.35) | HRH3KCNH2CYP2D6 | |
| SCHEMBL21733058 | 0.72 | MAPT (0.46) | HRH3ALDH1A1MAPT | |
| SCHEMBL28149214 | 0.69 | DPP4 (0.47) | HRH3F13A1TGM2TGM1ALDH1A1 | |
| SCHEMBL18704921 | 0.69 | HRH3 (0.53) | HRH3KCNH2CYP2D6 | |
| SCHEMBL18704932 | 0.69 | HRH3 (0.50) | HRH3KCNH2CYP2D6ALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1340/4885KCNH2 4007/4885CYP2D6 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.